Human papillomavirus (9-valent) vaccine is under clinical development by Xiamen Innovax Biotech and currently in Phase II for Human Papillomavirus Infections.

Zigakibart is under clinical development by Novartis and currently in Phase III for IgA Nephropathy (Berger's Disease).

Novaferon is under clinical development by Genova Biotech and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

TQB-2223 is under clinical development by Chia Tai Tianqing Pharmaceutical Group and currently in Phase I for Solid Tumor.

PAX-1 is under clinical development by Komipharm International and currently in Phase I for Kidney Cancer (Renal Cell Cancer).

Onvapegleukin alfa is under clinical development by Ascendis Pharma and currently in Phase II for Human Papillomavirus (HPV) Associated Cancer.

Icerguastat is under clinical development by InFlectis BioScience and currently in Phase I for Charcot-Marie-Tooth Disease Type I B.

MB-108 is under investigation for the treatment of recurrent glioblastoma multiform, malignant glioma, anaplastic astrocytoma and gliosarcoma. The therapeutic candidate is a next-generation HCMV/HSV-1 ...

EF-001 is under clinical development by Everfront Biotech and currently in Phase II for High-Grade Glioma. According to GlobalData, Phase II drugs for High-Grade Glioma does not have sufficient ...

Long-Acting Injectable Program is under clinical development by Intra-Cellular Therapies and currently in Phase I for Schizoaffective Disorder.

CSL -889 is under development for the treatment of acute vascular occlusive crisis (VOC) in sickle cell disease. The drug candidate consists of plasma-derived hemopexin. It is administered through ...

Abiraterone is under clinical development by Austhera BioSciences and currently in Phase II for Hormone-Sensitive Prostate Cancer.